Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Bavarian Nordic A/S (OTC: BVNRY).

Full DD Report for BVNRY

You must become a subscriber to view this report.

Recent News from (OTC: BVNRY)

Bavarian Nordic inks deal with U.S. DoD for equine encephalitis virus vaccine; shares up 3%
Bavarian Nordic A/S ( OTCPK:BVNRY +3.3% ) has secured $36M multiyear contract from the U.S. Department of Defense (DoD) to support the development of a prophylactic vaccine against the mosquito-borne equine encephalitis virus. More news on: Bavarian Nordic A/S ADR, Healthcare stocks ne...
Source: SeekingAlpha
Date: March, 16 2018 09:52
Bavarian Nordic Announces Partnership with U.S. Department of Defense to Combat Equine Encephalitis Virus
Collaboration valued up to $36M Multivalent vaccine designed to protect humans against Eastern, Venezuelan, and Western equine encephalitis virus COPENHAGEN, Denmark, March 16, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the signing of a new alliance with t...
Source: GlobeNewswire
Date: March, 16 2018 08:54
Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer
Bavarian Nordic and Bristol-Myers Squibb agree to supply clinical material for the trial Investigator-led study represents the fourth clinical combination of CV301 with a checkpoint inhibitor COPENHAGEN, Denmark, March 8, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today a...
Source: GlobeNewswire
Date: March, 08 2018 08:59
Bavarian Nordic Announces Additional Positive Data from a Phase 2 Study of its Universal RSV Vaccine
Presence of antibodies in nasal mucosa suggest vaccine-induced immune protection at source of infection IgA antibodies against RSV observed in both serum and mucosa of vaccinated individuals COPENHAGEN, Denmark, March  6, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) t...
Source: GlobeNewswire
Date: March, 06 2018 08:33
Bavarian Nordic Announces Collaboration to Evaluate CV301 in Combination with durvalumab in Colorectal and Pancreatic Cancers
Third evaluation of CV301 in combination with a checkpoint inhibitor Multicenter investigator-sponsored trial to be led by Georgetown University COPENHAGEN, Denmark, February 26, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced a new collaboration that will inve...
Source: GlobeNewswire
Date: February, 26 2018 04:40
Your Daily Pharma Scoop: Abeona Surges, Gilead Results, Biogen Setback
Analysis of top Seeking Alpha coverage: Abeona Today we will focus on Abeona Therapeutics ( ABEO ), which reported promising data for its gene therapy candidate for Sanfilipo B, an ultra-rare disease. Abeona today announced preliminary 30-day safety and biopotency signals from ...
Source: SeekingAlpha
Date: February, 08 2018 08:00
Bavarian Nordic's smallpox vaccine successful in late-stage study
A Phase 3 clinical trial evaluating Bavarian Nordic's ( OTCPK:BVNRY -8.4% ) INVAMUNE, a non-replicating smallpox vaccine, met both primary endpoints . More news on: Bavarian Nordic A/S ADR, Sanofi, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: February, 06 2018 13:36
Bavarian Nordic Announces Positive Results of Pivotal Phase 3 Study of IMVAMUNE® Smallpox Vaccine
Study successfully achieved both primary endpoints Second positive Phase 3 demonstrating the safety and efficacy of IMVAMUNE and final study required for licensure, as agreed with FDA BLA filing expected in second half of 2018 with fast track designation COPENHAGEN, Denmark, Fe...
Source: GlobeNewswire
Date: February, 06 2018 12:23
Bavarian Nordic Announces Initiation of Clinical Trial with Novel Cancer Immunotherapy Targeting Brachyury in Cancer Metastasis
Brachyury plays a key role in metastasis and progression of tumors and is overexpressed in several major, as well as orphan cancers COPENHAGEN, Denmark, January 19, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the initiation of a clinical trial of BN-Brachyury,...
Source: GlobeNewswire
Date: January, 19 2018 01:01
Bavarian Nordic Announces Exercise of Clinical Option by the US Government under Contract for Freeze-dried IMVAMUNE Smallpox Vaccine
Award of approximately USD 37 million will support clinical work required for product approval COPENHAGEN, Denmark, November 21, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Biomedical Advanced Research and Development Authority (BARDA) have exercised ...
Source: GlobeNewswire
Date: November, 21 2017 13:06


About Bavarian Nordic A/S (OTC: BVNRY)

Logo for Bavarian Nordic A/S (OTC: BVNRY)

Not available




Current Share Structure


    Daily Technical Chart for (OTC: BVNRY)

    Daily Technical Chart for (OTC: BVNRY)

    Stay tuned for daily updates and more on (OTC: BVNRY)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (OTC: BVNRY)

    Do your DD and if you choose, be ready to go!


    The Research: All source information contained in this email is from the public sources mentioned below.



    Thank you

    The Subway Trader



    Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BVNRY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of BVNRY and does not buy, sell, or trade any shares of BVNRY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: